Targeting Gatekeeper Mutations for Kinase Drug Discovery.

Area of Science:

• Oncology
• Pharmacology
• Structural Biology

Background:

• Acquired resistance to small-molecule kinase inhibitors (SMKIs) is a significant clinical challenge in cancer therapy.
• Gatekeeper mutations within the kinase ATP-binding pocket are the most frequent cause of this resistance.
• Despite FDA approvals of new-generation inhibitors, unmet clinical needs persist.

Purpose of the Study:

• To systematically review gatekeeper mutations across the kinome.
• To elucidate the structural basis of acquired resistance mediated by these mutations.
• To summarize novel SMKIs targeting gatekeeper mutations and discuss future drug discovery directions.

Main Methods:

• Systematic literature review of gatekeeper mutations in kinases.
• Analysis of structural data to understand resistance mechanisms.
• Survey of newly developed small-molecule kinase inhibitors targeting gatekeeper mutations.

Main Results:

• Categorization of gatekeeper mutation types and their prevalence in various kinases.
• Detailed structural insights into how gatekeeper mutations confer resistance to SMKIs.
• Identification and summary of emerging SMKIs designed to overcome gatekeeper-mediated resistance.

Conclusions:

• Gatekeeper mutations represent a critical hurdle in kinase inhibitor therapy.
• Understanding the structural basis of resistance is key to designing effective next-generation inhibitors.
• Further research and development are needed to address the ongoing challenge of acquired resistance in kinase-targeted cancer therapies.